SAN DIEGO, CA, Feb 05, 2014 (Menafn – Marketwired via COMTEX) –NuVasive, Inc. NUVA, a medical device company focused ondeveloping minimally disruptive surgical products and procedures forthe spine, is pleased to announce executive leadership changes thatwill foster the Company’s continued evolution into an increasinglyprofitable, 1 Billion Start-up(TM).
Effective February 1, 2014, Quentin Blackford was promoted to theExecutive Leadership Committee as Executive Vice President of Financeand Investor Relations. Blackford joined NuVasive in 2009, and withnearly 15 years of financial experience within medical deviceorganizations, his effort and insight will be invaluable as NuVasivedrives toward 1 billion and beyond in revenues with improvedprofitability.
The Company also announced the resignation of Craig Hunsaker, SeniorVice President of Global Human Resources, which will be effectiveMarch 31, 2014. Hunsaker will assist in the transition of hisresponsibilities to Mike Paolucci, who has been appointed ExecutiveVice President of Global Human Resources, effective immediately.
Mike Paolucci joins NuVasive from Life Technologies Corporation(TM),a global life sciences company with over 4 billion in revenue, whichwas recently acquired by Thermo Fisher Scientific. He brings morethan 20 years of broad global human resources experience at theexecutive and board level that will be instrumental to NuVasive’sevolution into a larger, global business. At Life Technologies,Paolucci was responsible for the global compensation and benefitprograms that encompassed more than 10,000 employees in nearly 40countries. He also served as a human resources business partner forvarious business segments and was responsible for the Company’s humanresources technology systems. Prior to Life Technologies, he servedas Vice President in various human resources capacities atHewlett-Packard and EDS Corporation, from 2000 to 2009.
Alex Lukianov, Chairman and Chief Executive Officer, said, “We areexceptionally grateful to Craig for all of his contributions duringhis tenure with NuVasive. I am thrilled to welcome both Quentin andMike to the NuVasive Executive Committee. Their strong propensity foroutstanding standards, steadfast focus, and wealth of experience inachieving excellent outcomes will be instrumental to our executiveleadership team. I look forward to their contributions and havetremendous confidence in the team we have organized to help usachieve our market share taking strategy.”
About NuVasive
NuVasive is an innovative global medical device company that ischanging spine surgery with minimally disruptive surgical productsand procedurally integrated solutions for the spine. The Company isthe 4th largest player in the 8.7 billion global spine market.
NuVasive offers a comprehensive spine portfolio of more than 90unique products developed to improve spine surgery and patientoutcomes. The Company’s principal procedural solution is its MaximumAccess Surgery, or MAS(R) platform for lateral spine fusion. MASprovides safe, reproducible, and clinically proven outcomes, and is ahighly differentiated solution with fully integrated neuromonitoring,customizable exposure, and a broad offering of application-specificimplants and fixation devices designed to address a variety ofpathologies.
Having pioneered the lateral approach to spine fusion, NuVasivecontinues to be at the forefront of the spine industry’s shift towardless invasive solutions. The Company’s dedication to innovationcontinues to spawn game changing technology such as the PCM(R) motionpreserving disc for the cervical spine, XLIF(R) Corpectomy for tumorand trauma, and Armada(R), which treats adult degenerative scoliosisin a less invasive fashion. The Company has also developed proceduralsolutions that completely redefine and improve upon traditionalprocedures like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive’ssolutions are increasingly being adopted internationally, as theCompany lays the groundwork to continue growing as a global businessand to offer industry-leading, Absolutely Responsive customer serviceto surgeons world-wide. NuVasive is focused on becoming a 1 BillionStart-up(TM); taking market share by maintaining a commitment toSuperior Clinical Outcomes, Speed of Innovation(R), and AbsoluteResponsiveness(R).
NuVasive cautions you that statements included in this press releasethat are not a description of historical facts are forward-lookingstatements that involve risks, uncertainties, assumptions and otherfactors which, if they do not materialize or prove correct, couldcause NuVasive’s results to differ materially from historical resultsor those expressed or implied by such forward-looking statements. Thepotential risks and uncertainties which contribute to the uncertainnature of these statements include, among others, risks associatedwith acceptance of the Company’s minimally disruptive surgicalproducts by spine surgeons, development and acceptance of newproducts or product enhancements, expansion of our network of salesrepresentatives, and the other risks and uncertainties described inNuVasive’s press releases and periodic filings with the Securitiesand Exchange Commission. NuVasive’s public filings with theSecurities and Exchange Commission are available at www.sec.gov.NuVasive assumes no obligation to update any forward-lookingstatement to reflect events or circumstances arising after the dateon which it was made.